CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: GlobeNewswire
BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces it has engaged with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities. This collaboration aims to enhance access to critical therapies for the estimated 40,000 veterans living with end-stage renal disease (ESRD) and other beneficiaries of federal programs. This engagement leverages WSI PBG's proven expertise in navigating the VA and other federal facilities, including access, procurement processes, and regulations, to meet the unique needs of federal healthcare systems. With a shared commitment to improving health outcomes, CorMedix and WSI PBG will work together to provide patients at the VA and ot
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix (NASDAQ:CRMD) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCathGlobeNewswire
- 5 High Earnings Yield Value Picks Ahead of Key Economic Reports [Yahoo! Finance]Yahoo! Finance
- Assessing CorMedix (CRMD): Is the Current Share Price Reflecting Its True Value? [Yahoo! Finance]Yahoo! Finance
- Cormedix Inc (CRMD) Q3 2025 Earnings Call Highlights: Record Financial Performance and ... [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 12/18/25 - Form 144
- 12/11/25 - Form 4
- 12/10/25 - Form 4
- CRMD's page on the SEC website